Gene editing player gets $25M in Series A round

Precision BioSciences nabbed $25.6 million in its initial funding round thanks to the likes of Fidelity Biosciences, Amgen Ventures, Baxter Ventures and Osage University Partners in support of its ARCUS gene editing platform. "We're an older genome editing company with the latest genome-editing technology," said the Duke spinout's CEO Matthew Kane. "ARCUS is a fully synthetic nuclease that we've developed here at Precision to overcome some of the key hurdles faced by the earlier technologies." The large sum of money dished out to the company demonstrates the wave of interesting in one of biotech's newest research paradigms. More

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.